Indeed, the classification of BC into different subtypes according to the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) enabled the design of hormone deprivation or anti-HER2 agents that led to improved survival outcomes for these patients [3]. This evidence concerns the gene PGR and breast cancer.